Clinical trial · no report yet · Phase 2
DEMETHER
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
- NCT06172127 ↗
- Active not recruiting
- MedSIR
- 20 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| X threads | 7 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtecan as Induction Treatment for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Trastuzumab deruxtecan; Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection; Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
- Arms
- T-DXd induction treatment phase followed by PHESGO maintenance treatment phase · Experimental
- Enrollment
- 165 (estimated)
- Primary outcomes
- 1-year PFS rate
- 3-year OS rate
- Sponsor
- MedSIR with Hoffmann-La Roche
- Start
- Jul 22, 2024
- Primary completion
- Apr 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06172127 · updated Apr 29, 2026